170 related articles for article (PubMed ID: 34345850)
1. Interpretation of murine local lymph node assay (LLNA) data for skin sensitization: Overload effects, danger signals and chemistry-based read-across.
Roberts DW
Curr Res Toxicol; 2021; 2():53-63. PubMed ID: 34345850
[TBL] [Abstract][Full Text] [Related]
2. Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals.
Gerberick GF; Ryan CA; Dearman RJ; Kimber I
Methods; 2007 Jan; 41(1):54-60. PubMed ID: 16938465
[TBL] [Abstract][Full Text] [Related]
3. Skin sensitization testing in potency and risk assessment.
Kimber I; Basketter DA; Berthold K; Butler M; Garrigue JL; Lea L; Newsome C; Roggeband R; Steiling W; Stropp G; Waterman S; Wiemann C
Toxicol Sci; 2001 Feb; 59(2):198-208. PubMed ID: 11158712
[TBL] [Abstract][Full Text] [Related]
4. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 2. The biological variability of the murine Local Lymph Node Assay (LLNA) for skin sensitisation.
Roberts DW; Api AM; Aptula AO
Regul Toxicol Pharmacol; 2016 Oct; 80():255-9. PubMed ID: 27470439
[TBL] [Abstract][Full Text] [Related]
5. Estimating skin sensitization potency from a single dose LLNA.
Roberts DW
Regul Toxicol Pharmacol; 2015 Apr; 71(3):437-43. PubMed ID: 25625585
[TBL] [Abstract][Full Text] [Related]
6. Chemistry-based risk assessment for skin sensitization: quantitative mechanistic modeling for the S(N)Ar domain.
Roberts DW; Aptula AO; Patlewicz GY
Chem Res Toxicol; 2011 Jul; 24(7):1003-11. PubMed ID: 21671633
[TBL] [Abstract][Full Text] [Related]
7. Novel approach for classifying chemicals according to skin sensitizing potency by non-radioisotopic modification of the local lymph node assay.
Takeyoshi M; Iida K; Shiraishi K; Hoshuyama S
J Appl Toxicol; 2005; 25(2):129-34. PubMed ID: 15744759
[TBL] [Abstract][Full Text] [Related]
8. Estimating uncertainty in LLNA EC3 data and its impact on regulatory classifications.
Chapkanov A; Schultz TW; Yordanova D; Kirilov K; Ivanova H; Mekenyan OG
Regul Toxicol Pharmacol; 2023 Mar; 139():105357. PubMed ID: 36805911
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the skin sensitization potency of eugenol and its dimers using a non-radioisotopic modification of the local lymph node assay.
Takeyoshi M; Noda S; Yamazaki S; Kakishima H; Yamasaki K; Kimber I
J Appl Toxicol; 2004; 24(1):77-81. PubMed ID: 14745850
[TBL] [Abstract][Full Text] [Related]
10. Use of the local lymph node assay in the evaluation of the sensitizing potential of pharmaceutical process intermediates.
Durand G; de Burlet G; Virat M; Nauman BD
Contact Dermatitis; 2003 Sep; 49(3):148-54. PubMed ID: 14678211
[TBL] [Abstract][Full Text] [Related]
11. Contact allergenic potency: correlation of human and local lymph node assay data.
Gerberick GF; Robinson MK; Ryan CA; Dearman RJ; Kimber I; Basketter DA; Wright Z; Marks JG
Am J Contact Dermat; 2001 Sep; 12(3):156-61. PubMed ID: 11526521
[TBL] [Abstract][Full Text] [Related]
12. The local lymph node assay and the assessment of relative potency: status of validation.
Basketter DA; Gerberick F; Kimber I
Contact Dermatitis; 2007 Aug; 57(2):70-5. PubMed ID: 17627643
[TBL] [Abstract][Full Text] [Related]
13. The impact of vehicle on the relative potency of skin-sensitizing chemicals in the local lymph node assay.
Jowsey IR; Clapp CJ; Safford B; Gibbons BT; Basketter DA
Cutan Ocul Toxicol; 2008; 27(2):67-75. PubMed ID: 18568891
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the performance of the reduced local lymph node assay for skin sensitization testing.
Ezendam J; Muller A; Hakkert BC; van Loveren H
Regul Toxicol Pharmacol; 2013 Jun; 66(1):66-71. PubMed ID: 23459101
[TBL] [Abstract][Full Text] [Related]
15. LLNA variability: An essential ingredient for a comprehensive assessment of non-animal skin sensitization test methods and strategies.
Hoffmann S
ALTEX; 2015; 32(4):379-83. PubMed ID: 26168096
[TBL] [Abstract][Full Text] [Related]
16. Predicting skin sensitizer potency based on in vitro data from KeratinoSens and kinetic peptide binding: global versus domain-based assessment.
Natsch A; Emter R; Gfeller H; Haupt T; Ellis G
Toxicol Sci; 2015 Feb; 143(2):319-32. PubMed ID: 25338925
[TBL] [Abstract][Full Text] [Related]
17. Local lymph node assay: use in hazard and risk assessment.
Dearman RJ; Basketter DA; Kimber I
J Appl Toxicol; 1999; 19(5):299-306. PubMed ID: 10513674
[TBL] [Abstract][Full Text] [Related]
18. Nothing is perfect, not even the local lymph node assay: a commentary and the implications for REACH.
Basketter DA; McFadden JF; Gerberick F; Cockshott A; Kimber I
Contact Dermatitis; 2009 Feb; 60(2):65-9. PubMed ID: 19207375
[TBL] [Abstract][Full Text] [Related]
19. Human potency predictions for aldehydes using the local lymph node assay.
Basketter DA; Wright ZM; Warbrick EV; Dearman RJ; Kimber I; Ryan CA; Gerberick GF; White IR
Contact Dermatitis; 2001 Aug; 45(2):89-94. PubMed ID: 11553118
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: an interlaboratory evaluation.
Kimber I; Hilton J; Dearman RJ; Gerberick GF; Ryan CA; Basketter DA; Lea L; House RV; Ladics GS; Loveless SE; Hastings KL
J Toxicol Environ Health A; 1998 Apr; 53(7):563-79. PubMed ID: 9561969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
